In the journal supplement to Current Psychiatry, diagnostic dilemmas and choosing the right treatment in patients with tardive dyskinesia (TD) were covered by Manish Jha, MBBS and Greg Mattingly, MD. These articles covered an overview of TD, identification of traditional treatment approaches to TD and their limitations, and details from recent research relating to the efficacy and safety of novel treatment options for TD.
To complete the evaluation and claim credit, please click “Begin Activity” at left and then “Claim Credit” on the next screen.
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Center for Depression Research and Clinical Care
Department of Psychiatry
UT Southwestern Medical Center
Associate Clinical Professor
Washington University School of Medicine
St Louis, Missouri
St Charles Psychiatry Associates
St Charles, Missouri
Executive Vice President, Educational Strategy
General Manager, Oncology
Chief Medical Officer
Clinical Education Alliance
New York, New York
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is intended for physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists engaged in the care of patients with psychiatric illness.
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.
CCO designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-175-H01-P.
Type of Activity: Knowledge
Upon successfully completing the post-test with a score of 70% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until October 31, 2022. PAs should only claim commensurate with the extent of their participation.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 29, 2021, through October 31, 2022:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Dr Greg Mattingly reviews the latest available clinical data for emerging diagnostic and therapy options for managing the mood disorders and TD, from Clinical Care Options (CCO)
Clinical Care Options (CCO) commentary by Sanjay Gupta, MD, on choosing the right VMAT2 inhibitor for TD
In this activity, a panel of Sanjay Gupta, MD reviews salient research studies of interest relevant to depression, schizophrenia, ADHD and substance abuse and provides clinical commentary
Commentary by Manish Jha, MD, on weight gain and metabolic differences in agents used for bipolar depression, from Clinical Care Options (CCO)